Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson’s disease study
Brain · 01.08.2024 · 147 (8) · 2652-2667
DOI: 10.1093/brain/awae188 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Brain, online erschienen am 01.08.2024. Verfasst von Ana Westenberger und 59 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Neurogenetics, University of Lübeck, University Medical Center Schleswig-Holstein, 23538 Lübeck, Schleswig-Holstein, Germany. Hauptthemen laut MEDLINE: Parkinson Disease, Genetic Testing, Leucine-Rich Repeat Serine-Threonine Protein Kinase-2. Die Arbeit wurde bisher 115-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS.
Abstract (Originalsprache)
Estimates of the spectrum and frequency of pathogenic variants in Parkinson’s disease (PD) in different populations are currently limited and biased. Furthermore, although therapeutic modification of several genetic targets has reached the clinical trial stage, a major obstacle in conducting these trials is that PD patients are largely unaware of their genetic status and, therefore, cannot be recruited. Expanding the number of investigated PD-related genes and including genes related to disorders with overlapping clinical features in large, well-phenotyped PD patient groups is a prerequisite for capturing the full variant spectrum underlying PD and for stratifying and prioritizing patients for gene-targeted clinical trials. The Rostock Parkinson’s disease (ROPAD) study is an observational clinical study aiming to determine the frequency and spectrum of genetic variants contributing to PD in a large international cohort. We investigated variants in 50 genes with either an established relevance for PD or possible phenotypic overlap in a group of 12 580 PD patients from 16 countries [62.3% male; 92.0% White; 27.0% positive family history (FH+), median age at onset (AAO) 59 years] using a next-generation sequencing panel. Altogether, in 1864 (14.8%) ROPAD participants (58.1% male; 91.0% White, 35.5% FH+, median AAO 55 years), a PD-relevant genetic test (PDGT) was positive based on GBA1 risk variants (10.4%) or pathogenic/likely pathogenic variants in LRRK2 (2.9%), PRKN (0.9%), SNCA (0.2%) or PINK1 (0.1%) or a combination of two genetic findings in two genes (∼0.2%). Of note, the adjusted positive PDGT fraction, i.e. the fraction of positive PDGTs per country weighted by the fraction of the population of the world that they represent, was 14.5%. Positive PDGTs were identified in 19.9% of patients with an AAO ≤ 50 years, in 19.5% of patients with FH+ and in 26.9% with an AAO ≤ 50 years and FH+. In comparison to the idiopathic PD group (6846 patients with benign variants), the positive PDGT group had a significantly lower AAO (4 years, P = 9 × 10−34). The probability of a positive PDGT decreased by 3% with every additional AAO year (P = 1 × 10−35). Female patients were 22% more likely to have a positive PDGT (P = 3 × 10−4), and for individuals with FH+ this likelihood was 55% higher (P = 1 × 10−14). About 0.8% of the ROPAD participants had positive genetic testing findings in parkinsonism-, dystonia/dyskinesia- or dementia-related genes. In the emerging era of gene-targeted PD clinical trials, our finding that ∼15% of patients harbour potentially actionable genetic variants offers an important prospect to affected individuals and their families and underlines the need for genetic testing in PD patients. Thus, the insights from the ROPAD study allow for data-driven, differential genetic counselling across the spectrum of different AAOs and family histories and promote a possible policy change in the application of genetic testing as a routine part of patient evaluation and care in PD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Neurogenetics, University of Lübeck, University Medical Center Schleswig-Holstein, 23538 Lübeck, Schleswig-Holstein, Germany.
- CENTOGENE GmbH, 18055 Rostock, Mecklenburg-Vorpommern, Germany.
- Institute of Medical Biometry and Statistics, University of Lübeck, University Medical Center Schleswig-Holstein, 23562 Lübeck, Schleswig-Holstein, Germany.
- Department of Clinical Project Management, IQVIA, 60549 Frankfurt am Main, Hessen, Germany.
- Department of Neurology, St. Olavs Hospital, 7006 Trondheim, Trøndelag, Norway.
- Department of Neuroscience, Norwegian University of Science and Technology, 7034 Trondheim, Norway.
ORCID-Profile: Ana Westenberger, Christian Beetz
Förderung
- NINDS NIH HHS
Zitieren
APA
Westenberger, A., Skrahina, V., Usnich, T., Beetz, C., Vollstedt, E. J., Laabs, B. H., Paul, J. J., Curado, F., Skobalj, S., Gaber, H., Olmedillas, M., Bogdanovic, X., Ameziane, N., Schell, N., Aasly, J. O., Afshari, M., Agarwal, P., Aldred, J., Alonso-Frech, F., …, & Gudesblatt, M. (2024). Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson’s disease study. Brain, 147(8), 2652-2667. https://doi.org/10.1093/brain/awae188
Vancouver
Westenberger A, Skrahina V, Usnich T, Beetz C, Vollstedt EJ, Laabs BH, et al. Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson’s disease study. Brain. 2024;147(8):2652-2667. doi:10.1093/brain/awae188
BibTeX
@article{Westenberger2024,
author = {Westenberger, Ana and Skrahina, Volha and Usnich, Tatiana and Beetz, Christian and Vollstedt, Eva-Juliane and Laabs, Björn-Hergen and Paul, Jefri J and Curado, Filipa and Skobalj, Snezana and Gaber, Hanaa and Olmedillas, Maria and Bogdanovic, Xenia and Ameziane, Najim and Schell, Nathalie and Aasly, Jan Olav and Afshari, Mitra and Agarwal, Pinky and Aldred, Jason and Alonso-Frech, Fernando and Anderson, Roderick and Araújo, Rui and Arkadir, David and Avenali, Micol and Balal, Mehmet and Benizri, Sandra and Bette, Sagari and Bhatia, Perminder and Bonello, Michael and Braga-Neto, Pedro and Brauneis, Sarah and Cardoso, Francisco Eduardo Costa and Cavallieri, Francesco and Classen, Joseph and Cohen, Lisa and Coletta, Della and Crosiers, David and Cullufi, Paskal and Dashtipour, Khashayar and Demirkiran, Meltem and de Carvalho Aguiar, Patricia and De Rosa, Anna and Djaldetti, Ruth and Dogu, Okan and Dos Santos Ghilardi, Maria Gabriela and Eggers, Carsten and Elibol, Bulent and Ellenbogen, Aaron and Ertan, Sibel and Fabiani, Giorgio and Falkenburger, Björn H and Farrow, Simon and Fay-Karmon, Tsviya and Ferencz, Gerald J and Fonoff, Erich Talamoni and Fragoso, Yara Dadalti and Genç, Gençer and Gorospe, Arantza and Grandas, Francisco and Gruber, Doreen and Gudesblatt, Mark},
title = {Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson’s disease study},
journal = {Brain},
year = {2024},
volume = {147},
number = {8},
pages = {2652--2667},
doi = {10.1093/brain/awae188}
}
EUVIMED